Konakion Mm Voor Kinderen

Phytomenadione, the active ingredient in Konakion Mm Voor Kinderen, is a Vitamin K1 presented as a pediatric formulation for intramuscular, intravenous, and oral use. It treats vitamin K deficiency bleeding and helps reverse warfarin anticoagulation in children.

GNH USA supplies Konakion Mm Voor Kinderen as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Konakion Mm Voor Kinderen provides vitamin K1 to address disorders of coagulation where vitamin K is deficient or antagonized.

- Vitamin K deficiency bleeding: restores activity of clotting factors II, VII, IX, and X to stop bleeding. - Warfarin anticoagulation reversal: re‑activates the clotting cascade in patients requiring rapid normalization of coagulation. - Coagulopathy due to impaired vitamin K metabolism: supports synthesis of functional clotting proteins.

Common Side Effects: - Injection site pain or erythema - Mild flushing or warmth sensation - Nausea or vomiting - Headache - Low‑grade fever - Transient dizziness

Serious or Rare Side Effects: - Anaphylactic reaction - Severe allergic dermatitis - Hemolysis - Thrombosis or embolic events - Hypotension requiring medical attention - Acute liver dysfunction

Before administering Konakion Mm Voor Kinderen, consider the following precautions: - Assess baseline vitamin K status: evaluate coagulation parameters. - Use caution in patients with liver disease: impaired synthesis of clotting factors may affect response. - Monitor for hypersensitivity: discontinue if severe allergic reaction occurs. - Adjust dose in newborns and infants: follow prescriber guidance closely. - Avoid concurrent use with high‑dose vitamin K antagonists without monitoring. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Phytomenadione may interact with several medications that affect coagulation.

Major Interactions (Avoid): - Warfarin or other vitamin K antagonists: may reduce anticoagulant effect. - High‑dose vitamin K supplements: can counteract intended therapeutic action.

Moderate Interactions (Monitor Closely): - Broad‑spectrum antibiotics (e.g., cephalosporins): may alter gut flora and vitamin K levels. - Oral contraceptives: potential additive effect on clotting risk. - Cholesterol‑lowering agents (statins): may influence vitamin K metabolism. - Antiplatelet drugs: monitor for enhanced bleeding control.